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Review
Inflammatory myofibroblastic tumour: a rare entity with wide 
differential diagnosis
S.M. Gilani, P.J. Kowalski
Inflammatory myofibroblastic tumour (IMT) is a rare, distinctive mes-
enchymal neoplasm. Grossly, it appears as a circumscribed mass with 
a rubbery to firm cut surface. Microscopically, it is characterized by a 
spindle cell proliferation within a myxoid stroma with admixed plasma 
cells, lymphocytes and eosinophils. Immunohistochemical staining is 
usually positive for vimentin, smooth muscle actin (SMA) and anaplastic 
lymphoma kinase (ALK). ALK gene rearrangement is present in approxi-
mately 50-70% IMTs. The standard treatment is surgical resection, and 
it is essential to differentiate IMT from benign and malignant mimick-
ers so that appropriate therapy may be provided. Clinical and radiological 
follow-up is required to detect recurrence.
Original article
Combined hepato-cholangiocarcinoma arising in a gallbladder 
intracystic papillary neoplasm. A new view on so-called  
“hepatoid adenocarcinoma of the gallbladder”
J.B. Dettoni, W. Andrauss, N.D. Theise, M.S. Rocha, E.S. Mello,  
C.H.L. Rocha, T.E.F. Pfiffer, V.A.F. Alves
A 62-year-old female presented with abdominal pain, weight loss of 20 
kg in the prior 6 months, and a palpable mass in the right upper quadrant 
during physical exam. Standard liver tests, including screening for hepa-
titis B and C and alpha-fetoprotein were negative or within normal lim-
its. Computerized tomography depicted a transmural gallbladder tumor 
infiltrating into the adjacent liver with an irregular ill-defined mass occu-
pying segments IV-V-VI, measuring 13.0 x 9.2 x 8.5 cm, with a solid-
cystic component and heterogeneous captation of endovenous contrast 
media. Complete surgical resection of the neoplasm was achieved 
through an extended cholecystectomy and excision of hepatic segments 
IV, V and VI, with an uneventful follow-up 18 months until now. Mor-
phological and immunohistochemical assessment favored a diagnosis of 
combined hepatocellular-cholangiocarcinoma arising in a gallbladder 
intracystic papillary neoplasm with invasive carcinoma. This case raises 
the hypothesis that the so-called “hepatoid adenocarcinoma of the gall-
bladder” may presently be better understood as a neoplasm derived from 
hepatobiliary stem/progenitor cells. Such cells have been recognized in 
the canals of Hering, in peribiliary glands within the liver and in the 
extrahepatic biliary tree, and in gallbladder mucosa.  
Case reports
A rare case of transmural endometriosis in primary  
adenocarcinoma of the rectum
M. Falleni, D. Bauer, E. Opocher, L. Moneghini, G.P. Bulfamante
Intestinal endometriosis of the rectum and sigmoid colon, occurring in 
up to 34% of pelvic endometriosis, mimics a wide number of condi-
tions that are difficult to differentiate from inflammatory or malignant 
diseases. Herein we report the first case of transmural endometriosis 
concomitant with advanced primary rectal adenocarcinoma, presenting 
with obstructive symptoms. Correct diagnosis based on morphologi-
cal identification and immunohistochemical characterization of the two 
entities is crucial for treatment. 
Collision tumour of the breast composed of Merkel cell  
carcinoma and invasive ductal carcinoma: a case report
D. Nedved, C. Connor, P. Sharma, M. O’Neil
We report a case of a 71-year-old female with a palpable breast 
mass. Pathologic evaluation of the breast mass showed a unique 
collision tumour with a high-grade invasive and in-situ ductal carci-
noma component and a high-grade neuroendocrine carcinoma com-
ponent. The neuroendocrine component turned out to be Merkel cell 
carcinoma (MCC), with immunohistochemical confirmation. To the 
best of our knowledge, this is the first case report of a collision 
tumour with ordinary ductal carcinoma and MCC in the breast.
Intestinal tuberculosis: a diagnostically-challenging case misdi-
agnosed as Crohn’s disease at colorectal biopsy
M. Onorati, D. Morganti, M. Bocchi, E. Colombo, G. Petracco,  
P. Uboldi, F. Di Nuovo
The clinical presentation of two different digestive diseases such as 
Crohn’s disease and intestinal tuberculosis may be so similar to induce 
a delay in correct diagnosis and appropriate treatment (immune sup-
pression versus antibiotic therapy). Herein, we describe the case of a 
young man from Eastern Europe who came to our observation com-
plaining of clinical symptoms initially misdiagnosed as an inflam-
matory bowel disease. It is important to keep in mind the possibility 
of an active tubercular disease, particularly in patients coming from 
countries endemic for the disease. Morphological findings of sarcoid-
like granulomas at biopsy is not enough for a conclusive diagnosis of 
Crohn’s disease, and tuberculosis should be ruled out on the basis of 
clinical information, laboratory tests and radiological imaging. 
Primary tumour of the round ligament of the liver:  
a case presentation 
J.A. Solarana Ortíz, J.E. Placencia Gilart, M. Rodríguez Diéguez,  
Z. Miranda Moles, M. Pullés Labadié, J.C. Lau Cuza,  
S. Corpas Fuster 
A 40-year-old Caucasian female patient presented to the outpa-
tient General Surgery ward in “V. I. Lenin” Teaching Hospital 
complaining of a recurrent mesogastric pain that had lasted for 3 
months. Physical examination showed a palpable mass confined to 
that area. She was then admitted with diagnosis of an abdominal 
tumour. Diagnostic work-up revealed that the process involved the 
round ligament of the liver, which is an exceptional localization, 
which motivated us to publish this case after surgical treatment by 
excision, having also taken into account the results of histopathol-
ogy which revealed a PEComa, confirmed by inmunohistochemis-
try. After reviewing the available literature, the low incidence of 
these lesions, as well as the unusual histological variety, makes the 
present case one of interest. 
Metastasizing pleomorphic adenoma of the submandibular gland:  
a case report
S. Miladi, S. Mestiri, W. Kermani, S. Ziadi, B. Sriha, K. Bouzouita,  
M. Mokni
Pleomorphic adenoma (PA), originally called mixed tumour, is 
the most common neoplasm of the salivary glands. It is usually a 
benign, slow-growing and well-circumscribed tumour. However, 
PA may occasionally give rise to metastases that usually occur 
after a previous recurrence. These tumours display benign his-
tological features in both primary tumours and metastases. Such 
tumours have been termed metastatic PA or metastatic mixed 
tumours. We report a case of metastatic PA of the submandibular 
gland with metastasis to the cervical lymph nodes.
Fibroadenoma in an ectopic vulvar breast gland:  
a common neoplasm in an uncommon site
A. Ayadi-Kaddour, A. Khadhar, M. Mlika, E. Braham, O. Ismail,  
D. Zegal, F. El Mezni 
Ectopic breast tissue is defined as glands located outside of the 
breast. It can be found anywhere along the milk line extending 
from the axilla to the groin, and can occur in the vulva. Ectopic 
breast tissue should be excised because it may develop benign or 
malignant pathologic processes. Less than 40 cases of fibroade-
noma in the vulva have been reported in the literature. We report 
a case of a 37-year-old woman presenting a solitary vulvar mass. 
The mass was excised completely, and histology demonstrated an 
ectopic breast fibroadenoma. This is one of the few reports on the 
benign pathologies of vulvar mammary glands.

pathologica 2014;106:1-6
Introduction
Inflammatory myofibroblastic tumour (IMT) is a rare 
mesenchymal proliferation. Much of what today is en-
compassed by IMT includes many lesions historically 
called inflammatory pseudotumour, plasma cell granu-
loma, omental-mesenteric myxoid hamartoma, etc. A re-
arrangement of the anaplastic lymphoma kinase (ALK) 
gene at chromosome 2p23 is present in approximately 
50% of IMTs, suggesting that this entity is a neoplas-
tic, as opposed to a reactive, process 1 2. IMT occurs in 
many body sites, but has been most frequently report-
ed in the viscera, soft tissue and lungs of children and 
adults. IMTs have a tendency for local tissue infiltration, 
occasional rapid growth, and local recurrence. IMT may 
be confused with not only neoplasms (malignant fibrous 
histiocytoma, dendritic cell neoplasms and myxoid fibro-
sarcoma), but also with benign, inflammatory conditions 
(inflammatory pseudotumour and nodular fasciitis). 
Clinical features and imaging
IMT may arise at any an anatomical site, with the lungs 
and retroperitoneum as the most common primary lo-
cations  3. Yu et al. found that IMT is one of the most 
common paediatric lung tumours 4. Other sites include 
gastrointestinal tract, omentum, mesentery, head and 
neck, central nervous system, orbit, spleen, soft tissues 
and genitourinary system (including bladder and pros-
tate) 3 5. Involvement of the colon and intestines is very 
rare, and may produce intestinal obstruction or intussus-
ception 6 7. IMT associated with Sjögren’s disease, sys-
temic lupus erythematosus and non-Hodgkin lymphoma 
of the lung has been reported 7 8. Associated laboratory 
findings include elevated erythrocyte sedimentation rate 
(ESR), variable white blood cell count (WBC), anaemia, 
thrombocytosis and hypergammaglobulinemia 2. 
Imaging studies, especially magnetic resonance imaging 
(MRI), may aid in identifying a mass lesion in involved 
tissues, however, a diagnosis of IMT cannot be made 
solely on radiologic findings. Positron emission tomog-
raphy (PET) scanning is helpful in evaluating the pres-
ence of local invasion, in assessing the aggressiveness of 
the lesion and in monitoring patient response after surgi-
cal resection 9.
Pathological features
IMTs usually present as a multilobular or well-circum-
scribed mass, with rubbery to firm cut surface, depending 
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Inflammatory myofibroblastic tumour (IMT) is a rare, distinctive 
mesenchymal neoplasm. Grossly, it appears as a circumscribed 
mass with a rubbery to firm cut surface. Microscopically, it is 
characterized by a spindle cell proliferation within a myxoid 
stroma with admixed plasma cells, lymphocytes and eosinophils. 
Immunohistochemical staining is usually positive for vimentin, 
smooth muscle actin (SMA) and anaplastic lymphoma kinase 
(ALK). ALK gene rearrangement is present in approximately 
50-70% IMTs. The standard treatment is surgical resection, and it 
is essential to differentiate IMT from benign and malignant mim-
ickers so that appropriate therapy may be provided. Clinical and 
radiological follow-up is required to detect recurrence.
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on the amount of myxoid stroma present. Focal haemor-
rhage, necrosis and calcifications may be present. The 
tumour size is variable ranging from 1 to 17 cm with a 
mean diameter of 6.4 cm 10.
IMTs have three classical architectural patterns. The 
most common is a proliferation of bland spindle or stel-
late-shaped cells distributed haphazardly within a vari-
ably myxoid stroma (Fig. 1) with admixed lymphocytes, 
plasma cells, neutrophils and eosinophils (Fig. 2). Less 
commonly, densely packed stromal cells are arranged 
in a storiform pattern with intermingled inflammatory 
cells. The third rarest pattern resembles a desmoid tu-
mour. In one study, it was demonstrated that all cases 
(100%) of IMTs showed infiltrative borders 10. Regard-
less of the pattern, the spindle-shaped myofibroblasts 
lack cytological atypia and nuclear pleomorphism. 
The myofibroblasts have eosinophilic to amphophilic 
cytoplasm and nuclei with open, vesicular chromatin 
(Fig. 3). Mitotic activity is variable but generally mini-
mal (1-2/high power field) and without atypical forms. 
Calcifications and foci of metaplastic bone may be seen. 
The morphologic spectrum varies from classic appear-
ing IMT to those with an atypical histologic appearance. 
Atypical morphological features include ganglion-like 
cells, abundant cellularity, nuclear pleomorphism, atyp-
ia and mitotic figures (typical and atypical). Historically, 
these features were thought to portend poor prognosis, 
but currently there is no evidence to support this 3. The 
rare epithelioid or round cell morphologic variant of IMT 
with aggressive clinical behaviour has been described in 
the literature. This pattern shows neoplastic cells that are 
round to epithelioid in appearance, disposed in a myxoid 
back ground with admixed inflammatory infiltrates. A 
less prominent spindle cell component and foci of ne-
Fig. 1. haematoxylin-eosin-stained section highlighting prolifera-
tion of spindle cells distributed evenly in the myxoid appearing 
stroma with background inflammatory cells (original magnifica-
tion x 100).
Fig. 2. haematoxylin-eosin-stained section showing the admix-
ture of spindle cells, plasma cells and lymphocytes (original mag-
nification x 200).
Fig. 3. haematoxylin-eosin-stained section showing the myofi-
broblasts with abundant, eosinophilic to amphophilic, fibrillary 
cytoplasm. there are background lymphocytes, plasma cells, 
neutrophils and eosinophils (original magnification x 400).
Fig. 4. immunohistochemical staining with smooth muscle actin 
(SMa) demonstrating diffuse staining of myofibroblasts. (original 
magnification x 200).
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crosis can be seen. The mitotic activity is variable. Im-
munohistochemically, neoplastic cells exhibit predomi-
nantly a nuclear membrane staining pattern and, less 
frequently, cytoplasmic expression of ALK 11. 
The evaluation of IMT on frozen sections is a diagnostic 
challenge as it can mimic various reactive and neoplas-
tic lesions. Immunohistochemically, the myofibroblastic 
spindle cells are frequently immunoreactive for vimentin, 
smooth muscle actin (SMA) (Fig. 4), muscle-specific ac-
tin and less frequently for desmin, cytokeratin and CD68. 
Cytoplasmic immunoreactivity with anaplastic lympho-
ma kinase (ALK) in 50-70% of cases has also been dem-
onstrated in IMT (Fig. 5) 9. ALK expression has also been 
reported in other non-IMT mesenchymal tumours (malig-
nant peripheral nerve sheath tumour, rhabdomyosarcoma, 
leiomyosarcoma and malignant fibrous histiocytoma) 
which raise the possibility that a subset of mesenchymal 
neoplasms harbour a common mutation, although the ex-
act mechanism is not clear 12. IMT can show variable cel-
lular atypia, nuclear pleomorphism, elevated mitotic ac-
tivity with atypical mitotic figures, overexpression of p53 
and aneuploidy, but these findings have no proven cor-
relation as a predictor of aggressive behaviour 12. Over-
expression of Ki-67 is usually seen in highly proliferative 
lesions.
Ultrastructurally, the spindle cells that compose IMTs 
exhibit a poorly-developed Golgi apparatus and rough 
endoplasmic reticulum, as well as abundant extracellular 
collagen consistent with myofibroblastic and fibroblas-
tic differentiation 12 13.
Genetics and biology
Recent genetic findings have played a crucial role in con-
ceptualizing IMT as a neoplastic process, while the impor-
tance of molecular findings regarding biologic behaviour 
remains uncertain. IMTs have been shown to exhibit cy-
togenetic clonal rearrangement of the anaplastic lympho-
ma kinase (ALK) gene on chromosome 2p23 14  15. This 
abnormality can be detected by conventional cytogenet-
ics, florescence in-situ hybridization (FISH) and reverse 
transcription polymerase chain reaction in approximately 
50% of IMTs 16-18. A fusion gene involving tropomyosin 
(TPM) N-terminal coiled domains and ALK C-terminal 
domain may play a key role in pathogenesis 19. Other fu-
sion genes, including tropomyosin 3 gene (TPM3), tro-
pomyosin 4 gene (TPM4), SEC31 homolog A (S. cer-
evesiae) (SEC31L1), ran-binding protein 2 (RANBP2), 
cysteinyl-tRNA synthetase (CARS) and clathrin heavy 
chain gene (CTLC), have also been reported  3 19 20. Im-
munohistochemical staining with ALK and p80 are often 
overexpressed, both of which are indicators of the 2p23 
abnormality  21-23. However, the immunohistochemical 
staining pattern of ALK gene is variable depending on 
the type of the fusion gene. This can be cytoplasmic in 
TPM3, TPM4 and SEC31L1 fusion, while RANBP2 fu-
sion products exhibit nuclear expression 11. Some authors 
suggest that RANBP2 gene fusion may be associated 
with IMTs having an aggressive clinical course 11 18. 
In one study, Coffin et al. demonstrated patients with 
ALK-negative IMTs are typically older adults, whose 
tumours have increased frequency of metastases and 
atypical mitoses. In contrast, ALK-positive IMTs were 
associated with younger age and increased frequency of 
local recurrences 3 22. However, morphologic evaluation 
cannot reliably predict ALK status in any individual case. 
ALK-negative tumours pose the additional problem of 
being more difficult to separate from alternative diagno-
ses, including both inflammatory and neoplastic entities. 
ALK-negative cases are, in practicality, considered most 
likely neoplastic, based upon similar histology with 
ALK-positive tumours. However, this is controversial 
and reflects a lack of understanding regarding the full 
impact of ALK-negativity. Molecular abnormalities, in 
association with a better understanding of biologic po-
tential, may eventually supplant histologic classification 
for ALK-negative tumours. 
The presence of an ALK abnormality also raises the 
question as to its significance as a prognostic factor in 
IMT. While ALK chromosome translocations {t(1;2)
(q25;p23)}, along with the expression of other markers, 
may have prognostic significance in anaplastic large cell 
lymphoma (ALCL), this cytogenetic correlation is as yet 
unclear in IMT 24 25. 
The ALK positive IMT patients may receive targeted 
therapy. Crizotinib, an ALK inhibitor, in conjunction 
with surgery may be useful in ALK positive cases that 
are complicated by local recurrence whereas ALK nega-
tive IMT are nonresponsive to crizotinib 26.
Differential diagnosis
The differential diagnosis of IMT is quite broad and, 
depending on the anatomic site, includes inflammatory 
pseudotumour, dendritic cell neoplasms, low-grade sar-
Fig. 5. immunohistochemical staining with anaplastic lymphoma 
kinase (alK) showing diffuse staining of myofibroblasts. (original 
magnification x 200).
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comas, sarcomatoid variant of ALCL, low grade myo-
fibroblastic sarcoma and nodular fasciitis. These enti-
ties can share some common histopathological findings. 
However, their clinical behaviour is highly variable. In-
flammatory pseudotumour (IPT) is a non-neoplastic in-
flammatory lesion that is not limited to myofibroblasts. 
In the past, some have considered IPT and IMT to be 
synonymous terms but according to review of the current 
literature, molecular and immunophenotypic findings 
have helped to separate these entities 1 14 18. While the di-
agnoses of IMT and IPT have been used interchangeably, 
IPT can now be regarded as a heterogeneous group of 
lesions, composed of various amounts of inflammatory 
cells and fibrosis that may mimic a neoplasm on imag-
ing studies, but it is not neoplastic 27. IMT and IPT share 
certain histologic features; however a high mitotic count 
and proliferative index, cytologic atypia, positive ALK 
immunoreactivity and rapid recurrence after initial resec-
tion are supportive of a diagnosis of IMT. A dendritic cell 
neoplasm consists of uniform, oval-to-spindle cells with 
smooth nuclear membranes and background lympho-
cytes. Follicular dendritic cells stain positive for CD21 
and CD35, and interdigitating dendritic cell tumours are 
immunoreactive with CD1a. Low-grade sarcomas like 
myxoid fibrosarcomas are characterized by a prolifera-
tion of bland appearing spindle cells with focal atypia 
and a background that is more fibrous than myxoid. Sar-
comatoid variant of ALCL shares some of the histologic 
features such as storiform pattern and myxoid stroma 
with IMT but, like ALCL, is T-cell in origin which is not 
true for IMT 17. Nodular fasciitis is characterized by fi-
broblasts arranged in short bundles and fascicles. The in-
tervening matrix is rich in mucopolysaccharides and the 
spindle cells are bland, without significant atypia. Some 
chronic inflammatory cells may be seen in the stroma.
In cases with lung involvement, all of the above di-
agnoses and, in addition, solitary fibrous tumour may 
potentially be considered in the differential diagnosis. 
Solitary fibrous tumours consist of fibroblast-like cells 
in a patternless arrangement, with hypocellular- and hy-
percellular areas separated by thick, hyalinized collagen 
with cracking artefact and a haemangiopericytoma-like 
vascular pattern. These tumours usually stain positively 
for CD34 and CD99. 
The differential diagnosis is variable according to the site 
of presentation. Desmoid tumours may be considered in 
the differential diagnosis, especially if IMT is involving 
the abdominal region. Desmoid tumours show a myofi-
broblastic proliferation set within a variable amount of 
collagen. A subset of desmoid tumour is associated with 
beta catenin mutation  27. They have less inflammation 
compared to IMT and do not express ALK. 
IMT can involve the urinary bladder, and in these cases, a 
postoperative spindle cell nodule (PSCN), a pseudosarco-
matous myofibroblastic proliferation, is also a diagnostic 
consideration. The pathogenesis of PSCN is uncertain, as 
is its classification as a neoplastic or reactive process 28 29. 
However, the presence of a prior history of instrumenta-
tion and injury with a resulting spindle cell myofibroblas-
tic proliferation favours a reactive process. Grossly, it ap-
pears as a sessile nodule with ulceration. Histologically, it 
shows a proliferation of spindle cells with an admixture of 
inflammatory cells, hemosiderin-laden macrophages and 
extravasated red cells. Mitotic activity is usually variable 
with absence of atypical mitosis. Focal areas of necrosis 
with surrounding inflammatory cells can be seen corre-
sponding to the previous surgery site. IMT share many 
histologic features with PSCN which makes differentia-
tion difficult on morphologic evaluation alone. However, 
the history of recent instrumentation, proximity to the 
instrumentation site and bland fascicular growth pattern, 
facilitates its recognition. 
If IMT is suspected in the paediatric age group, fibro-
sarcoma and leiomyosarcoma may be included as di-
agnostic considerations. The characteristic histologic 
appearance and immunohistochemical staining pattern 
of each entity helps to differentiate it from IMT. Fibro-
sarcoma usually shows an infiltrative growth pattern 
with malignant spindle cells arranged in herringbone 
fashion. The cells show cytologic atypia, pleomor-
phism and abundant mitoses. They can demonstrate 
variable expression for smooth muscle actin (SMA) 
and vimentin, while they are negative for S-100 and 
CD-34. Leiomyosarcomas are smooth muscle tumours 
and are characterized by a malignant spindle cell pro-
liferation arranged in interweaving fascicles. They 
demonstrate expression for SMA and desmin. 
Treatment
Surgical resection is the mainstay of treatment of IMT 
in order to prevent recurrence and to rule out malig-
nancy. Systemic corticosteroids aid in improving a pa-
tient’s overall clinical condition and promote regres-
sion of disease 30. Bertocchini et al. emphasizes the role 
of adjuvant anti-inflammatory drugs and chemotherapy 
in the resolution of the clinical symptoms 31. Some au-
thors have also suggested a role for post-operative ra-
diotherapy 32.
Prognosis
IMT is a neoplastic proliferation of myofibroblasts 
that usually follows an indolent and benign clinical 
course. There is a potential for recurrence and per-
sistent local growth, similar in some respects to fi-
bromatosis. The rate of local recurrence is variable 
for different sites of the body, including 25% for 
abdominal and pelvic region. Lu et al. described a 
case of IMT in a 14 year old with high mitotic index, 
recurring 20 days after complete resection 33. Metas-
tasis to other sites is very rare with only a few cases 
having been reported 34 35. Hagenstad et al. reported a 
case of abdominal IMT with metastasis to bone mar-
row  35. In a review of 46 cases, Montgomery et al. 
described 2 patients with IMT and co-existing sarco-
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matoid carcinoma of the bladder, while one patient 
with malignant IMT, having positive ALK gene re-
arrangement, showed morphologically sarcomatoid 
features. That patient did not respond to chemother-
apy, showed multiple recurrences and died within a 
few months due to metastatic disease 5. Sarcomatoid 
transformation and rapidly progressive disease lead-
ing to metastasis suggest malignant IMT 5. However, 
in a study of 59 IMT, Coffin et al showed 6 cases 
with metastatic disease with negative ALK by im-
munohistochemistry. Of those 6 cases, 3 were with 
atypical morphologic features 3. In a series of 11 cas-
es, Mariño-Enríquez et al. described 2 cases of IMT 
with epithelioid morphology showing distant metas-
tasis and, overall, 5 patients dying due to aggressive 
disease 11. These findings raise the possibility of ma-
lignant behaviour with IMT, but this is unclear and 
needs further study.
Conclusion
Inflammatory myofibroblastic tumour is a neoplasm 
with intermediate biologic behaviour that very rarely 
presents with advanced features such as local invasion, 
recurrence and malignant transformation with distant 
metastasis  35. The use of ALK immunohistochemistry 
and molecular studies including cytogenetics are im-
portant diagnostic tools. IMT may be suspected preop-
eratively due to haematologic abnormalities and radio-
logic findings, but tissue from a biopsy or surgical re-
section is required for adequate and accurate histologic 
confirmation. Careful histopathologic evaluation of the 
lesion is necessary so as not to mistake IMT for other 
benign and malignant conditions. Complete surgical 
resection, if possible, is the recommended treatment. 
Follow-up is required to detect recurrence and prevent 
complications.
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Introduction 
The so-called “hepatoid adenocarcinoma” is a rare ma-
lignant tumor recognized along the biliary tract and other 
extra-hepatic niches, depicting morphologic and immu-
nophenotypic resemblance to hepatocellular carcinoma 
(HCC) which is essential for its identification. The pres-
ent case report as well as some recently published case 
reports provide evidence that hepatoid adenocarcinomas 
of the gallbladder and extrahepatic biliary tree are de-
rived from biliary progenitor cells with bidirectional 
differentiation towards hepatocytes and cholangiocytes, 
thus supporting a novel view that the so-called “hepatoid 
adenocarcinomas” might be better understood as a com-
bined hepatocellular-cholangiocarcinoma (cHCC-CC) 
arising in the biliary tree. 
Materials and methods 
Case report 
A 62-year-old Caucasian female presented with ab-
dominal pain and weight loss of 20  kg in the prior 6 
months, accompanied by diarrhea after food intake and 
weakness. Past medical history included hypertension, 
Chagas disease and type II diabetes mellitus, without 
evidence of previous hepatobiliary disease. She denied 
smoking or alcohol consumption. During physical ex-
am, a palpable mass was found at right upper quadrant 
without jaundice. Standard liver tests, including screen-
ing for hepatitis B and C, were within normal limits or 
negative. She was anaemic (haemoglobin 9.8 g/dl) and 
her white blood cell count was increased (20.7 103/_l). 
Laboratory tests for metabolic profile and serum alpha-
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A 62-year-old female presented with abdominal pain, weight 
loss of 20 kg in the prior 6 months, and a palpable mass in the 
right upper quadrant during physical exam. Standard liver tests, 
including screening for hepatitis B and C and alpha-fetoprotein 
were negative or within normal limits. Computerized tomogra-
phy depicted a transmural gallbladder tumor infiltrating into the 
adjacent liver with an irregular ill-defined mass occupying seg-
ments IV-V-VI, measuring 13.0 x 9.2 x 8.5 cm, with a solid-cys-
tic component and heterogeneous captation of endovenous con-
trast media. Complete surgical resection of the neoplasm was 
achieved through an extended cholecystectomy and excision of 
hepatic segments IV, V and VI, with an uneventful follow-up 
29 months until now. Morphological and immunohistochemi-
cal assessment favored a diagnosis of combined hepatocellular-
cholangiocarcinoma arising in a gallbladder intracystic papillary 
neoplasm with invasive carcinoma. This case raises the hypoth-
esis that the so-called “hepatoid adenocarcinoma of the gallblad-
der” may presently be better understood as a neoplasm derived 
from hepatobiliary stem/progenitor cells. Such cells have been 
recognized in the canals of Hering, in peribiliary glands within 
the liver and in the extrahepatic biliary tree, and in gallbladder 
mucosa. 
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fetoprotein (AFP = 2.8 ng/ml) were normal. Computer-
ized tomography (CT) showed a transmural gallbladder 
tumor as an irregular ill-defined mass infiltrating liver 
segments IV, V and VI, measuring 11.6 x 9.8 x 8.6 cm. 
The tumor had solid and cystic components with het-
erogeneous captation of endovenous contrast media. 
A gallstone was also found (Fig. 1). 
Complete surgical resection of the neoplasm was 
achieved through an extended cholecystectomy and ex-
cision of hepatic segments IV, V and VI. The outcome 
was uneventful, with normal laboratory values and no 
residual tumor on image. The patient did not receive any 
adjuvant therapy, chemotherapy or radiotherapy. After 
29 months of follow-up, the patient remains free of tu-
mor recurrence. Based on the clinical observations and 
gross findings, the tumor was considered to have arisen 
in the gallbladder and infiltrating surrounding liver. 
Results 
Pathology 
Grossly, the specimen showed an ill-defined mass with 
infiltrative borders, measuring 12.0 x 9.0 x 8.5 cm, with 
whitish, firm areas intermingled with extensive necro-
sis. The tumor clearly appeared to be primarily located 
in the gallbladder mucosa wall, depicting progressive 
thickening of gallbladder wall with mucosal ulceration 
Fig. 1. abdominal enhanced ct: a. axial image: heterogeneous mass in liver segments iV and V. B. coronal image: irregular and heterogenous 
transmural gallbladder mass in continuity with infiltration of adjacent liver parenchyma. c. coronal image (more posterior than B): Mass pre-
dominantly in the gallbladder lateral wall.
Fig. 2. Microscopic findings: a-B: calculous chronic cholecystitis with cholesterolosis and papillary formations (h&E 50x and 100x); c-D: 
transition with intracystic papillary neoplasm with areas of dysplasia and papillary formation (h&E 50x and 100x); E-F: transition of high 
grade dysplasia with solid, “glassy cell, poorly differentiated cholangiocarcinoma”, invading through the gallbladder wall and adjacent liver 
parenchyma (h&E 50x and 100x).
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and infiltration into surrounding liver parenchyma. 
The adjacent gallbladder wall was thickened and had a 
grey-white appearance. The lumen contained a mixed 
stone and the mucosa had an irregular appearance. 
The remaining liver parenchyma showed a grossly normal 
architecture without grossly evident fibrosis or cirrhosis. 
There was no macroscopic evidence of vascular invasion.
Microscopically, the gallbladder mucosa showed a back-
ground of calculous chronic cholecystitis and cholestero-
losis within which there was an intracystic papillary neo-
plasm, extending into Rokitansky-Aschoff sinuses. There 
was high grade biliary intra-epithelial neoplasia (BilIN-3) 
that was continuous with a solid component, of poorly 
differentiated cholangiocarcinoma, composed of inter-
mingled small and large cells, extensively invading the 
gallbladder wall and adjacent liver parenchyma (Fig. 2). 
Deeper in the liver (Fig.  3), the tumor showed poorly 
differentiated, but hepatocyte-like cells growing in solid, 
trabecular or pseudo-acinar patterns typical of HCC ad-
mixed with small cells, resembling hepatobiliary stem/
progenitor cells. Mitotic figures were frequent and ne-
crosis was multifocal. No bile production was seen, but 
hyaline globules were noticed within the cytoplasm of 
larger cells (Fig. 3). The normal architecture of the sur-
rounding liver was preserved, except for focal mild sinu-
soidal dilatation and lymphocytic infiltration probably 
Fig. 3. Microscopic findings: a-B: Solid, trabecular or pseudo-acinar carcinoma with a predominance of poorly differentiated polygonal 
hepatocytes with central, variably atypical vesicular nuclei with large nucleoli. Dispersed small cells, resembling “oval cells”, are seen. (h&E 
50x and 100x); c: Sirius red stain (SR 50x); D: Reticulin (50x); E: Vascular microinvasion (h&E 50x); F: the surrounding liver was non-cirrhotic/
fibrotic and without features of biliary disease or hepatitis (h&E 50x).
Tab. I. immunohistochemistry panel (c - canalicular; M - membranous; Sc - small cell).
Antibody Papillary Adenocarcinoma Solid/sclerosing “Conventional HCC” Glandular hyperplasia (DR)
K8 3+ 3+ 2+ (sc 3+) 3+
K7 3+ 3+ 1+ (sc 1+) 3+
K19 3+ 2+ 1+ (sc 1+) 3+
hep par 1 1+ 1+ 3+ 1+
pcEa c+M c+M canalicular c+M
arginase 0 0 0 0
lactoferrin 0 1+ 0 2+
cDX2 0 0 0 0/1 goblet
MUc1 3+ 3+ 1+ 3+
MUc2 1+ 0 0 2+
MUc5ac 1+ 0 0 2+
cD56 0 0 0 2+
cD133 0 0 0 2+
Vimentin 0 0 0 0
EgFR 0 2+ 2+ 0
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due to the nearby space occupied by the lesion. Features 
of chronic hepatitis, metabolic disease or chronic biliary 
tract disease were not seen. 
Immunohistochemistry 
Immunohistochemical staining for hepatocellular, bili-
ary, endothelial, stem/progenitor cell and other differ-
entiations were performed; the summary of results is 
provided in Table I and in Figures 4 and 5. Muc-1 was 
diffusely positive in non-neoplastic gallbladder muco-
sa, in intracystic papillary neoplasia and in its invasive 
component. As the tumour invaded liver parenchyma, 
the components with hepatocellular morphology de-
picted lower and more focal reactivity to Muc-1. On the 
other hand, HepPar-1 was diffusely positive in HCC ar-
eas and focal in the intraepithelial papillary component, 
Fig. 4. immunohistochemistry panel: a-B. MUc-1 diffusely positive in intraepithelial and invasive papillary neoplasia and in solid, poorly dif-
ferentiated cholangiocarcinoma. hepatocellular component depicted more focal reactivity. c-E. hcc areas diffusely positive for hep par-1 
and only focally reactive in papillary cholangiocarcinoma. F-g. hcc positive for pcEa on canalicular structures. papillary and solid compo-
nents of cholangiocarcinoma presented circumferential membranous and cytoplasmic reactivity. h. cD34 showing “diffuse capillarization” 
in hcc areas.
Fig. 5. Keratin markers: a. Keratins 8/18 (K8/18) positive in all components; B-E. K7 (B and c) and K19 (D and E) depicted a double cell popu-
lation in cholangiocarcinoma, with stronger reactivity in small cells. in contrast, hcc areas were either negative or only focally reactive for 
K7 and for K19.
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but negative in areas of invasive cholangiocarcinoma. 
Focal immunoreactivity was found in the intraepithe-
lial papillary component. As expected, HCC areas were 
positive for pCEA on cell membranes, especially mark-
ing canalicular structures, while both papillary and solid 
components of cholangiocarcinoma had circumferential 
membranous and cytoplasmic reactivity. CD34 reactiv-
ity in endothelial membranes showed “sinusoidal capil-
larization” in areas of HCC (Fig. 4). 
CAM5.2 stain for keratins 8/18 (K8/18) and stains for 
keratins 7 and 19 (K7, K19) were positive in all com-
ponents of cholangiocarcinoma, with stronger reactivity 
in small cells. As expected, contrasting with these chol-
angiocellular areas, the HCC areas, while positive for 
K8/18, were either negative or only focally reactive for 
K7 and K19 (Fig. 5). Immunostaining for hepatobiliary 
stem/progenitor cell markers (CD56, CD133) was nega-
tive. Other markers (see Tab. I) were also negative. 
Discussion
The radiological, morphological and immunohisto-
chemical findings in the present case favour a diagnosis 
of cHCC-CCa arising in an intracystic papillary biliary 
neoplasm from the gallbladder. Histomorphology further 
suggests “stem cell features” within the mixed tumour. 
The smooth transition of the in situ papillary lesion of 
the gallbladder to solid, poorly differentiated cholangio-
carcinoma (with an admixture of small and large chol-
angiocytes), and then to extensive areas of conventional 
appearing HCC, is closely similar to previous reports of 
hepatoid adenocarcinoma of the gallbladder, thus lead-
ing us to suggest the hypothesis that “hepatoid adenocar-
cinomas” of gallbladder, extra-hepatic biliary tract and 
pancreas might be better understood as cHCC-CCa with 
a probable origin in hepatobiliary stem/progenitor cells. 
Allen and Lisa first described the features of cHCC-
CC in 1949 1 as an infrequent hepatic neoplasm defined 
as a tumour containing components of both HCC and 
cholangiocarcinoma intimately admixed, as seen in the 
present case. Dual differentiation towards hepatocytes 
and bile duct epithelia coexist in this neoplasm  2 and, 
although a few several studies regarding the clinical and 
pathological features of cHCC-CC are now available, in-
formation about clinical outcome after hepatic resection 
is still contradictory. There is a lack of data regarding 
treatment of advanced cHCC-CC. Even the larger case 
series are unable to guide systemic therapy 3. The feel-
ing that cHCC-CC may have an unfavourable behaviour 
compared to ordinary HCC might derive from the fact 
that most of patients with cHCC-CC had high histologi-
cal grade tumours and advanced stage disease at the time 
of presentation 4-6. The presence of gross portal invasion 
and thrombosis has been related to worse prognosis of 
patients with cHCC-CC 4. In the present case, the pap-
illary component showed features of intra-cholecystic 
papillary–tubular neoplasm (ICPN), which has recently 
been reported to be a more indolent gallbladder adeno-
carcinoma, even when invasive  7. Although no gross 
vascular invasion was noticed in the present case, micro-
invasion was detected in portal vein branches (Fig. 3). 
Classification of cHCC-CC has been a matter of contro-
versy and thus, reports like the present and other series 
of cases can add clinical and morphological clues that 
are potentially useful for further understanding these 
intriguing neoplasms. While some studies propose that 
these neoplasms are a cholangiocarcinoma reproducing 
the pattern of small biliary ducts 8, others consider they 
could be a subtype of HCC or derive from hepato-biliary 
stem/progenitor cells 9. According to the current WHO 
classification, tumour cells of cHCC-CC with predomi-
nantly prominent features of hepato-biliary stem/pro-
genitor cells are regarded as cHCC-CCs “with stem cell 
features”, which have further been subdivided into three 
subtypes: typical, intermediate cell and cholangiolocel-
lular subtype  9  10. Genetic studies of cHCC-CC found 
gene expression profiles favouring activation of hepato-
biliary stem/progenitor cells, and genetically closer to 
CC than to conventional HCC 11. 
Hepato-biliary stem cells have been progressively de-
tected in different niches along the biliary tree in the 
normal human liver. Initial studies based on three-di-
mensional analysis of injured human and murine livers 
identified the canal of Hering as a stem cell niche 12 13, 
though others have been postulated. In vivo identifica-
tion of stem cell niches by label-retaining cell assay has 
been performed, confirming the canal of Hering as one 
such niche, but also supporting others previously hy-
pothesized: isolated cholangiocytes within the small to 
medium bile ducts themselves, peribiliary hepatocytes 
and periductal null cells  14. Activation of stem cells in 
one or more of these niches gives rise to transient ampli-
fying cells, with bipotent, hepatobiliary differentiation 
and rapid proliferation; these are considered hepatobili-
ary progenitor cells. In humans, these have been called 
the “intermediate hepatobiliary cell” component of the 
ductular reaction; in rodents, they are referred to as oval 
cells  12-14. Given the impossibility (so far) to reliably 
distinguish stem cells from their progenitor cell prog-
eny on the basis of morphology and immunophenotype, 
they are usually described in disease or malignancy as 
“stem/progenitor cells”, reflecting the continuity of their 
immunophenotypic, cytologic and functional charac-
teristics along a spectrum. The immunohistochemical 
profiles confirm mixed biliary and hepatocytic immu-
nophenotypes: OV-6, K19, K7, HepPar 1, epithelial 
cell adhesion molecule (EpCAM), neural cell adhesion 
marker (NCAM-1, CD56) and stem cell markers in-
cluding CD117 and CD34, amongst others 17. Ductular 
reactions display this spectrum, although with disease 
specific variations, in a variety of disorders including al-
coholic and non-alcoholic fatty liver disease, cholestatic 
liver disease, chronic hepatitis, submassive necrosis 
and in acute-on-chronic events  18 19. Microarray analy-
sis demonstrates up-regulation of genes related to liver 
stem/progenitor cells in a ductular reaction in subjects 
with alcoholic hepatitis. These genes include KRT7, 
J.B. Dettoni et al.12
SOX9, EpCAM, KRT19, PROM1, CD44 and others 20. 
In neoplasms, stem/progenitor cell phenotypes have 
been reported in both benign and malignant tumours 21-
26. The two most common primary liver carcinomas are 
HCC and cholangiocarcinoma; in most cases these are 
easily distinguished on the basis of morphology; how-
ever, in poorly differentiated tumours or in tumours with 
mixed phenotypes, immunohistochemistry is often nec-
essary for complete evaluation. Hepatocytic markers in-
clude HepPar-1, Arginase-1 and the canalicular pattern 
of immunostaining with CD10 or polyclonal anti-CEA. 
Although not specific, K7, K19 and mucins (especial-
ly Muc-1, Muc-5AC and Muc-6) are more frequently 
found in cholangiocarcinoma or in cHCC-CC. However, 
HepPar-1 is not fully specific, since it may be present 
in gallbladder epithelium and occasionally even in other 
adenocarcinomas from the respiratory tract, gynaeco-
logical tumours, digestive tract, genitourinary tract and 
neuroendocrine tumours 27-29. In the case reported here-
in, we found HepPar-1 positivity in tumour cells and in 
gallbladder intra-epithelial neoplasm. With regard to or-
dinary cholangiocarcinoma, recent histological and mo-
lecular characterization highlights the heterogeneity of 
this cancer emerging at different sites of the biliary tree 
with different macroscopic or morphological features 30. 
Considering the current case, recent reports ascribe the 
origin of mixed carcinomas of the gallbladder to hepato-
biliary progenitor cells 21 31. Moreover, additional stem 
cell niches have been identified in peribiliary glands of 
the extrahepatic and large intra-hepatic bile ducts as well 
as in the gallbladder 32. These sites could be sources of 
malignantly transformed, tumour generating stem/pro-
genitor cells. We also raise the possibility that previous-
ly-reported cases of the rare hepatoid adenocarcinoma 
of the gallbladder are also evidence of malignant trans-
formation of gallbladder hepato-biliary stem/progenitor 
cells 33. 
Differential diagnoses of hepatoid adenocarcinomas in 
this setting include HCCs or cHCC-CCs invading the 
gallbladder. Immunohistochemically, the component 
with hepatoid features diffusely expresses HepPar-1, 
pCEA and CD10, but not K7, whereas the well-differ-
entiated tubular-papillary adenocarcinoma is immuno-
reactive for K7, but not for AFP, HepPar-1, pCEA or 
CD10 32. 
In conclusion, detailed morphologic and immunohisto-
chemical assessment of this case suggests that the so-
called “hepatoid adenocarcinoma of the gallbladder” 
may presently be better understood as part of the spec-
trum of cHCC-CC, and that these may arise in the gall-
bladder, and not only in the liver itself. As to whether the 
neoplasm is derived from malignant transformation of 
hepato-biliary stem/progenitor cells, this case does not 
settle the question. On the one hand, hepatobiliary stem 
cells have been identified in niches within the gallblad-
der mucosa and peribiliary glands 32, and thus they could 
undergo malignant transformation. On the other hand, 
the present finding of the fact that the tumour arising 
in a pre-existing biliary in situ neoplasm in continuity 
with a progressively invasive that then gives rise to ad-
enocarcinoma further as it invades, which in turn dis-
plays hepatocellular phenotypes and morphology when 
growing into the liver environment, may also support the 
possibility that some of these tumours are derived from 
altered differentiation of a primarily adenocarcinoma, 
intracystic papillary biliary neoplasm (ICPN). The pos-
sible role of the hepatic environment in modulating such 
differentiation is particularly intriguing and raises ques-
tions about the role of microenvironment in the develop-
ment and differentiation of biliary malignancies. 
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Case report
A 50-year-old female with no significant past clinical 
history presented with abdominal pain and obstruction 
symptoms. After diagnostic workup indicative of rectal 
obstructive cancer with liver metastasis, she underwent 
proctosigmoidectomy and hepatic segmentectomy. A 
rectal vegetating mass with luminal stenosis infiltrated 
the full thickness of the intestinal wall. Multiple white 
nodules ranging from 0.6 to 3 cm in greatest dimension 
were found in the hepatic specimen. At the microscopic 
level, glandular structures from the subserosal tissue to 
the luminal intestinal surface were observed. At high-
er magnification, moderately differentiated malignant 
glands with necrotic areas were intermingled with cystic 
glands composed of focally ciliated cells, with minimal 
atypia and no mitotic activity, often surrounded by loose 
connective tissue. The lesion was tested for cytokeratin 
7 (OV-TL 12/30), cytokeratin 20 (K20.8), CEA(II-7), 
CDX2 (AMT28), oestrogen (1D5) and progesterone 
(636) receptor immunoreactivity. Neoplastic glands 
showed strong immunoreactivity only for cytokeratin 
20, CDX2 and CEA, and were documented in all intes-
tinal layers and in perivisceral fat. The second glandular 
component immunostained for cytokeratin 7 and for oes-
trogen and progesterone receptors antigens; it was pre-
dominantly sited in the subserosal fat and in the intesti-
nal muscular walls, but also in the submucosa and in the 
deeper portion of mucosa. A diagnosis of colonic adeno-
carcinoma of the classic type, associated with transmu-
ral endometriosis implants, was made. Metastasis of the 
adenocarcinomatous component to locoregional lymph 
nodes and in the hepatic specimen, and to the salpinges 
one year later, were found. At gynaecological controls, 
the patient was negative for atypical endometrial hyper-
plasia and/or endometrial carcinoma. No mutations in 
codons 12 and 13 of KRAS or in codon 600 of BRAF 
were found in either the colonic or metastatic lesions.
Discussion 
Differential diagnosis of the intestinal lesion is braod. 
Clinical and histological aspects of intestinal endometri-
osis may be confusing and pathologists should be aware 
of diagnostic pitfalls. 
Obstructive diseases of the recto-sigmoidal tract to be 
considered are: ischaemic disease, diverticular disease, 
Crohn’s disease and malignancies; in pre/peri-meno-
pausal women, intestinal endometriosis, reported to oc-
cur in up to 34% of pelvic endometriosis, should be kept 
in mind 1-6. Malignant transformation of endometriosis is 
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Intestinal endometriosis of the rectum and sigmoid colon, occur-
ring in up to 34% of pelvic endometriosis, mimics a wide number 
of conditions that are difficult to differentiate from inflammatory 
or malignant diseases. Herein we report the first case of transmural 
endometriosis concomitant with advanced primary rectal adenocar-
cinoma, presenting with obstructive symptoms. Correct diagnosis 
based on morphological identification and immunohistochemical 
characterization of the two entities is crucial for treatment. 
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uncommon, but intestinal endometrioid or clear cell ad-
enocarcinomas, and endometrial stromal sarcomas have 
been reported 2-5.
Architectural glandular pattern of endometriosis can 
resemble those of ischaemia, inflammatory bowel dis-
eases and/or ulcerative inflammation and infiltrating 
adenocarcinoma. At higher magnification, the presence 
of endometrial stroma surrounding bland glands is ex-
tremely useful to recognize endometriosis, but it is not 
always present, even in serial sections. Cellular atypia, 
mitotic activity and necrosis are useful to identify malig-
nant structures. Intestinal endometriosis and its possible 
malignant transformation should always be kept in mind 
in fertile and post-menopausal women with intestinal 
symptoms. 
This case, presenting with intestinal obstructive symp-
toms, shows that endometriosis can be associated with 
colon cancer. Correct diagnosis, strictly depending on 
immunohistochemical characterization of the lesion, is 
crucial for treatment. As colon cancer staging guides 
oncological treatment, it is extremely important not to 
misinterpret the concurrent endometriosis as colonic 
neoplastic proliferation, thus overstaging and overtreat-
ing the patient.
Fig. 1. glandular proliferation throughout muscular intestinal layers of the large bowel (haematoxylin and eosin, 2X). Double glandular 
components of the lesion with colorectal carcinoma glands (a: haematoxylin and eosin, 20X; B: cytokeratin 20 immunoreactivity, 20X) and 
endometriotic implants (c: haematoxylin and eosin, 20X; D: cytokeratin 7 immunoreactivity, 20X).
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Case presentation
A 71-year-old Caucasian female presented to her prima-
ry care physician with a palpable right breast mass. The 
patient was unsure how long the mass had been present 
and had never had a mammogram. She did not report 
any prior history of hormone replacement therapy or 
family history of breast cancer. Clinical breast exam re-
vealed a palpable mass in the upper outer quadrant with 
mild skin retraction over the mass. Ultrasonography 
demonstrated a hypoechoic, heterogenous solid mass 
with irregular borders, measuring 1.5 cm in its greatest 
dimension, and the result of a diagnostic mammogram 
was compatible with that of the ultrasound. Needle core 
biopsy revealed a high grade neuroendocrine neoplasm 
associated with high-grade ductal carcinoma in situ 
(DCIS) with comedo necrosis. Immunohistochemistry 
demonstrated the neuroendocrine component to be posi-
tive for cytokeratin (CK) 8 (CAM 5.2), synaptophysin, 
neurofilaments, chromogranin A, and CK 20. In par-
ticular, CK 20 showed characteristic dot-like positivity. 
CK 7 and thyroid transcription factor-1 (TTF-1) were 
negative in the neuroendocrine component. Ki-67/MIB-
1 immunostaining demonstrated a proliferative index of 
approximately 90% in the neuroendocrine component. 
In contrast, the DCIS was positive for CK7 and CK8 and 
negative for CK 20, neurofilaments, chromogranin A 
and synaptophysin. The DCIS component showed 95% 
and 75% positivity for oestrogen (ER) and progesterone 
receptor (PGR), respectively. MCC was negative for ER 
and PGR. A diagnosis of Merkel cell carcinoma (MCC) 
associated with high grade DCIS of the breast was made.
Lumpectomy with sentinel lymph node biopsy was 
planned. At the time of the surgical procedure, one 
month after the ultrasound was performed, it was noted 
that the palpable mass measured approximately 5 cm in 
size and the sentinel lymph node frozen section was pos-
itive for metastatic tumour consistent with MCC. Thus a 
right modified radical mastectomy was performed. The 
mastectomy specimen demonstrated a palpable mass 
measuring 4.5 cm in its greatest dimension adjacent to a 
previous biopsy site cavity. On permanent sections, his-
tologic examination revealed a MCC (comprising 80% 
of the overall tumour bed) intimately admixed with high 
grade comedo DCIS (Fig. 1) (approximately 20% of the 
overall tumour bed) and a small 2 mm focus of poorly 
differentiated invasive ductal carcinoma (Fig.  2). Im-
munohistochemistry was repeated on the entire tumour 
mass and showed identical results to the needle biopsy 
sample (Figs. 3-5). In addition, the invasive component 
showed an identical immunophenotype to the DCIS. 
HER-2/neu immunohistochemistry showed 1+ staining 
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We report a case of a 71-year-old female with a palpable breast 
mass. Pathologic evaluation of the breast mass showed a unique 
collision tumour with a high-grade invasive and in-situ ductal carci-
noma component and a high-grade neuroendocrine carcinoma com-
ponent. The neuroendocrine component turned out to be Merkel 
cell carcinoma (MCC), with immunohistochemical confirmation. 
To the best of our knowledge, this is the first case report of a colli-
sion tumour with ordinary ductal carcinoma and MCC in the breast. 
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of the invasive and in-situ ductal carcinoma and no stain-
ing of the MCC component. Subsequent fluorescence in 
situ hybridization for HER-2 detected no amplification 
in any of the components. Despite clinical suspicion, the 
overlying skin was free of tumour. Two additional sepa-
rate satellite tumour nodules of MCC (each measuring 
<0.5 cm and located 2.0 cm from the main tumour mass) 
were present. Of the 23 lymph nodes submitted, six were 
positive for metastatic MCC, and none were positive for 
metastatic breast carcinoma.
Follow-up
Post-operative staging with computed tomography (CT) 
scan of the chest, abdomen and pelvis and a positron emis-
Fig. 1. image showing two tumours: the solid growth pattern of 
blue cells with vesicular nuclei of the Mcc is seen on the left (aster-
isk) while a more eosinophilic large duct filled with DciS with com-
edo necrosis is seen on the right (arrow). (haematoxylin and eosin).
Fig. 2. this image shows scattered malignant epithelial nests of the 
invasive ductal carcinoma component (arrows) intimately admixed 
with Mcc on both sides (asterisks). (haematoxylin and eosin).
Fig. 3. A: Mcc featured by solid sheets of basophilic monomorphic cells with a high mitotic count, and high nuclear:cytoplasmic ratio (hema-
toxylin and Eosin). B: Mcc showing diffuse, strong positivity for cK 8/caM 5.2 (immunoperoxidase). C-D: Diffuse strong cytoplasmic positivity 
for both chromogranin (c) and neurofilament proteins (D) with dot-like features (immunoperoxidase).
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sion tomography (PET) scan demonstrated multiple meta-
static tumour nodules within the liver. Biopsy revealed 
metastatic MCC. Systemic chemotherapy with etoposide 
and carboplatin was recommended. However, the patient 
developed postmastectomy chest wall flap necrosis and 
chest wall wound healing problems, and thus chemothera-
py could not be started and radiation therapy could not be 
recommended. Therefore, after an octreotide scan was ob-
tained which showed activity in the liver lesions, therapy 
with Sandostatin LAR Depot was initiated. Unfortunately 
within the next two weeks the patient developed rapidly 
progressive liver disease, acute cholecystitis, local chest 
wall recurrence, renal failure and declining physical sta-
tus. The patient and family opted for palliative measures 
and the patient succumbed to her disease just four months 
after her initial presentation. For completeness and due to 
the particularly aggressiveness of MCC in this case, while 
preparing this manuscript, we studied the immunohisto-
chemical expression of p63, since this marker has been 
shown to correlate with prognosis and survival. The MCC 
component showed focal weak p63 staining with Ventana 
790-4509 clone 4A4.
Discussion
Merkel cell carcinoma (MCC) is an aggressive cuta-
neous tumour of older Caucasian individuals with a 
predilection for sun exposed areas 1, which was first 
described by Toker in 1972 as trabecular carcinoma 
of the skin 2. Exceptional cases outside the skin, such 
as those primarily arising on mucosal surfaces of the 
oral cavity  3, rhinopharynx  4, conjunctiva  5, and va-
gina 6 have been recorded. MCC is occasionally seen 
also in a lymph node (mainly inguinal) in the absence 
of a primary skin tumour, either as an occurrence sec-
ondary to the regression of the cutaneous primary 7 or 
as a tumour primarily arising from intranodal neuro-
endocrine cells 8. A handful of cases of primary MCC 
of the breast have been reported as well  9-14. Micro-
scopically, MCC is composed of nests and strands 
of monomorphic cells with a high mitotic count and 
a high nuclear: cytoplasmic ratio  15. Immunohisto-
chemical studies are generally required for diagnosis 
and for distinguishing MCC from other mimickers. 
In this particular case, the main histopathologic dif-
Fig. 4. A: in-situ and invasive ductal carcinoma showing strong positivity for cK 7. B: Mcc is negative for cK 7. (immunoperoxidase).
Fig. 5. A: cK 20 immunohistochemical stain depicting the paranuclear dot-like positivity (indicated by arrows) in the Mcc tumour compo-
nent. B. the invasive ductal carcinoma is negative for cK 20. (immunoperoxidase).
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ferential diagnostic considerations included neuroen-
docrine carcinoma of the breast (so-called carcinoid 
of the breast, Cubilla-Woodruff type), invasive duc-
tal carcinoma of breast with neuroendocrine features, 
metastatic small cell (neuroendocrine) carcinoma 
from other sites (mainly the lung), and primary small 
cell carcinoma of the breast, now qualified as pul-
monary type, which occasionally was called Merkel-
like carcinoma of the breast in the past. Generally, 
MCC will stain positive for CK20 (in a characteristic 
paranuclear, dot-like pattern), chromogranin A, syn-
aptophysin, neuron-specific enolase, and CK8/CAM 
5.2, and is negative for TTF-1 and CK 7 15. Neuroen-
docrine carcinoma of the breast (so-called [primary] 
carcinoid tumour) is also positive for neuroendocrine 
markers, such as chromogranin A, synaptophysin, and 
neuron-specific enolase, but does not show positiv-
ity for CK20. Neuroendocrine differentiation can also 
occur in invasive breast carcinoma NOS and in some 
special types, such as mucinous carcinoma and solid 
papillary carcinoma: these tumours will characteristi-
cally stain positive for CK7 and negative for CK20 
and neurofilament proteins (the converse is true for 
most MCC) 16. Metastatic neuroendocrine carcinoma, 
large cell type and small cell type from another site 
to the breast is usually positive for TTF-1 as well as 
negative for both CK20 and neurofilament proteins, 
while the overwhelming majority of MCC are nega-
tive for TTF-1 and positive for both CK20 and neu-
rofilament proteins  17. Primary small cell carcinoma 
of the breast, of which around 50 cases have been re-
corded in the literature, is often positive for TTF-1 
and usually negative for CK20 18.
Recent studies revealed the presence of a novel poly-
omavirus in Merkel cell carcinoma, aptly named 
Merkel cell polyomavirus (MCPyV). Initially found 
in eight of 10 MCC patients by Feng et al. 19, that re-
search was expanded to include 39 more patients with 
MCC who also were positive for the same polyoma-
virus 20. However, the clinical importance of MCPyV 
infection on prognosis, detection, and treatment has yet 
to be firmly established. There is a reported diagnos-
tic role of immunohistochemistry for MCPyV which 
is highly specific. However, sensitivity for MCPyV is 
not high, ranging from 18-67% in limited case series 21-
24. MCPyV positivity was initially claimed to corre-
late with worse prognosis and shorter survival, even 
though this concept was not confirmed by further stud-
ies which, while not disclosing any statistically signifi-
cant difference in survival between MCPyV positive 
and negative tumors on one hand, on the other discov-
ered that p63 is a better immunohistochemical marker 
for prognosis in MCC  25. In our case, an immunohis-
tochemical antibody stain for MCPyV was performed, 
using clone CMB2B4, directed against the Merkel cell 
virus large T-antigen, and was negative (courtesy of 
Dr. Dominic Spagnolo, of PathWest Laboratory Medi-
cine, Western Australia). p63 in our case showed focal 
faint positivity. 
The recommended treatment for MCC is usually sur-
gery (wide local excision of primary tumour along 
with regional lymph node dissection). Radiation ther-
apy can be effective as an adjunct, and chemotherapy 
is employed for metastatic tumours. In one case with 
metastatic MCC Sandostatin was employed with good 
clinical response after receptors for somatostatin were 
demonstrated using OctreoScan 26. Along this line, in 
our case a course of Sandostatin was administered for 
three consecutive days with the plan for injections ev-
ery three weeks with hope for long-term treatment. Un-
fortunately, the patient developed liver failure, thought 
to be of multifactorial aetiopathogenesis due to both 
tumour burden in the liver and octreotide toxicity. 
Shortly thereafter, the patient developed acute renal 
injury, secondary to dehydration, and the patient was 
started on hospice. 
Reported cases of primary MCC of the breast have oc-
curred in patients 52 to 93 years old, with one male pa-
tient documented  9-11 13 14. Tumour size at presentation 
ranged from 1.7 to 10 cm, and rapid growth was reported 
in most cases. One case demonstrated  metastasis  into 
the spinal canal compressing the medullary cord and 
causing paralysis  9. Another case (relevant to the male 
patient) reported no lymph node or distant metastases 
during a follow-up period of 5 years  10 [follow-up in-
formation received from one of the authors, Ahmed Al-
zaraa, who was contacted for the purpose of this publica-
tion], whereas another case reported lymph node metas-
tases in 14 of 22 lymph nodes 13.
The unique feature in our case is that the MCC is in-
termixed with a high-grade comedo DCIS and invasive 
ductal carcinoma of the breast. 
Second concurrent malignancies in the same as well as 
different anatomic sites are not uncommon in patients 
with MCC. Brenner et al. 27 reported 25% of patients 
diagnosed with MCC had a second malignancy diag-
nosed either previously or shortly thereafter. Gass et 
al.  28 reported that as many as 70% of patients with 
MCC had a second primary malignant tumour. The 
majority of the second malignancies were additional 
cutaneous tumours, such as melanoma, squamous cell 
carcinoma and basal cell carcinoma. A minority of pa-
tients presented with non-cutaneous malignancies in-
cluding colorectal, haematological and breast tumours 
(lobular carcinoma). It has been proposed that the sec-
ond neoplasm itself may represent a predisposing im-
munocompromised condition for development of MCC 
or both tumours may be the result of a generalized im-
munocompromised state 27 28. 
However, while concurrent MCC with a second neo-
plasm is common (around 40% of cases), collision tu-
mours between MCC and other malignancies are quite 
rare. A collision tumour is a generic term for the ex-
tremely uncommon coexistence or merging of two his-
tologically distinct malignant tumours within the same 
mass. Reported collision tumours with MCC include 
squamous cell carcinoma, either in situ or invasive  29, 
chronic lymphocytic leukaemia involving the skin  30 
D. NeDveD et al.20
and melanoma  31. Additionally, mixed MCC showing 
squamous or eccrine foci of differentiation (bipheno-
typic differentiation), or squamous, glandular and me-
lanocytic foci (tripartite differentiation) have been also 
recorded 29, attesting to the origin of MCC from a mul-
tipotential stem cell of ectodermal derivation, but even 
heterologous (leiomyosarcomatous, rhabdomyoblas-
tic, fibrosarcomatous) differentiation or dedifferentia-
tion have been reported both in primary and metastatic 
MCC 32-34. 
In conclusion, to the best of our knowledge and based on 
a search of the literature, a collision tumour with ductal 
breast carcinoma (either ordinary or special type) and 
MCC has not previously been reported.
Conclusion
Merkel cell carcinoma represents a highly deadly skin 
tumour, usually affecting sun-exposed areas and im-
munocompromised hosts. A unique case of a collision 
tumour with MCC and high-grade invasive and in-situ 
ductal carcinoma presenting as a breast mass is present-
ed herein. The particularly rapid progression of local 
and systemic disease in this patient is consistent with the 
known unfavourable prognosis of MCC. Pathologists 
should be aware of the possibility of such an occurrence 
as the prognosis and management of both invasive duc-
tal carcinoma with neuroendocrine differentiation and 
primary neuroendocrine carcinomas of the breast are 
markedly different from those of MCC. 
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Introduction
Crohn’s disease and intestinal tuberculosis (TBC) have 
a different aetiology, but share several common clini-
cal and histological features, raising diagnostic prob-
lems. These two diseases require different therapeutic 
approaches, immunosuppressive in Crohn’s disease 
while antibiotic in tuberculosis, with possible injury to 
the patient if prolonged immunosuppressive treatment 
is administered during an on-going bacterial infection. 
If a correct diagnosis of intestinal tuberculosis may be 
suspected in areas of high tubercular endemic rate, this 
is not the case in geographical areas such as Europe, es-
pecially Western Europe, where tuberculosis is rarely 
seen. We describe the case of a 28-year-old man ad-
mitted to Garbagnate Milanese Hospital for recurrent 
abdominal pain lasting one year, accompanied by nau-
sea and vomiting. In the absence of complete clinical 
data, he was misdiagnosed as suffering from Crohn’s 
disease. 
Case report
A 28-year-old male immigrant from Moldova was ad-
mitted to our hospital in Garbagnate Milanese for a co-
lonoscopy, requested by his physician because of recur-
rent abdominal pain of one year duration, accompanied 
by nausea and vomiting. He did not complain of bowel 
disorders, but of a progressive weight loss, about 14 kg 
from the beginning of symptoms. He had no significant 
past medical history except for acute bronchitis one year 
before. On colonoscopy, the left and transverse colon 
appeared to be macroscopically normal, while multi-
ple discrete longitudinal ulcerations with fibrin depos-
its were seen along the entire ascending colon. In the 
most proximal portion of the right colon these ulcera-
tions merged with one another. The caecum appeared 
macroscopically normal, except for prominent signs 
of mucosal inflammation and narrowing of the ileoce-
cal valve, so that the ileum was not explored. The bi-
opsies of lesions were fixed in formalin and stained 
with haematoxilin and eosin. Microscopically, samples 
taken from rectum, sigmoid and left colon showed mild 
to moderate chronic and acute inflammation, with eo-
case repOrt
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The clinical presentation of two different digestive diseases 
such as Crohn’s disease and intestinal tuberculosis may be so 
similar to induce a delay in correct diagnosis and appropri-
ate treatment (immune suppression versus antibiotic therapy). 
Herein, we describe the case of a young man from Eastern 
Europe who came to our observation complaining of clinical 
symptoms initially misdiagnosed as an inflammatory bowel 
disease. It is important to keep in mind the possibility of an 
active tubercular disease, particularly in patients coming from 
countries endemic for the disease. Morphological findings of 
sarcoid-like granulomas at biopsy is not enough for a conclu-
sive diagnosis of Crohn’s disease, and tuberculosis should be 
ruled out on the basis of clinical information, laboratory tests 
and radiological imaging. 
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sinophilia, glandular distortion and scattered foamy his-
tiocytes in the lamina propria. Samples taken from the 
proximal segments showed a pattern of severe chronic 
and acute inflammation, with eosinophilia and scattered 
erosions or frank ulcers, with foci of acute cryptitis, 
rare cryptic microabscesses and a mild degree of glan-
dular distortion. A prominent histological feature was 
the presence of sarcoid-like granulomas without necro-
sis (Fig. 1). In consideration of this last characteristic 
and clinical data, a histological diagnosis of idiopathic 
chronic inflammatory bowel disease, suggesting active 
Crohn’s disease, was made. Treatment with prednisone 
1 mg/kg and mesalazine 3 g/day was started. The pa-
tient had a partial improvement of his general condition, 
followed by a subsequent slow worsening. Physical 
examination of the abdomen was normal, except for a 
slight pain in the right groin, without any further weight 
loss. Steroid treatment was maintained. Two weeks later 
the patient was examined again. He reported 1-2 bow-
el movements a day, with solid stools and no trace of 
blood. He also claimed moderate weakness, slight ab-
dominal pain and occasional nausea. Slow tapering of 
the steroid treatment was continued without reducing 
the dose of mesalazine. A few days later the patient re-
turned because of vomiting and hyporexia. Meanwhile, 
he had spontaneously withdrawn steroid treatment. He 
reported progressive weight loss. The gastroenterologist 
consulted decided to hospitalize the patient for further 
investigation and therapeutic adjustment. During hospi-
talization steroid treatment was re-started, with a modest 
and temporary improvement of general conditions, fol-
lowed by the reappearance of abdominal pain, nausea 
and vomiting. Due to the initial diagnosis and dyspeptic 
symptoms, an oesophagogastroduodenoscopy was also 
performed, which revealed a wide ulcer at the beginning 
of the descending duodenal segment. Biopsy samples, 
taken to rule out a duodenal localization of Crohn’s dis-
ease, were consistent with a peptic ulcer. Moreover, a 
cytological examination of a brushing from distal oe-
sophagus disclosed mycosis. Based on these findings, 
treatment with a biological drug was discussed by clini-
cians. Before the administration of infliximab, Mantoux 
and Quantiferon tests, together with HBV, HCV, HIV 
viral markers and a chest X-ray were performed. All 
Fig. 1 a, b, c. Submucosal non-necrotizing granulomas in colonic biopsy specimens. the granulomas are often poorly formed and show a 
sarcoid-like aspect with scattered giant cells.
[a: haematoxylin-eosin (h&E); original Magnification (o.M.): 20x; B: h&E; o.M.: 40x; c: h&E; o.M.: 10x]
a b
c
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these exams were normal, except for the chest X-ray, 
which revealed scattered nodular lesions consistent with 
possible tubercular disease. Laboratory tests showed a 
neutrophilic leucocytosis and a slight increase in eryth-
rocyte sedimentation rate (ESR) and C-reactive protein 
(CRP). A chest and abdomen computed tomography CT 
was performed, which disclosed multiple pulmonary 
nodular lesions, with a diameter ranging from 6 to 23 
mm, mainly peripherally and subpleurically placed, in 
upper right pulmonary lobe and lower and upper left 
lobes. Nodular calcifications and excavations were also 
seen. Blurred and soft hyperdense spots, adjacent to the 
nodules, compatible with tubercular lesions, were seen 
subpleurally, without any feature of pleural or pericar-
dial effusion. Oval shaped lymph nodes were present in 
the Barety’s space and in pre- and subcarenal positions, 
with a maximum size of 15 mm. CT of the abdomen 
showed a thickening of the colonic walls, more marked 
in caecum and ascending colon, and of the last ileal loop 
as well as the ileocecal valve. The pneumologist called 
for consultation decided to perform a bronchoscopy, 
which showed a hyperaemic, friable and easily bleeding 
bronchial mucosa. A bacteriological culture performed 
on a smear from brochoaspirated material revealed the 
presence of alcohol–acid resistant bacteria, while on 
laboratory tests an increase in biochemical indexes of in-
flammation was seen. Steroid treatment was withdrawn 
and the patient was promptly transferred to a specialized 
bronchopneumological ward, where further investiga-
tions confirmed a pulmonary tuberculosis. Treatment 
with rifampicin, isoniazide, pyrazinamide and ethambu-
tol was started. The biopsies taken on the first colonos-
copy were revised by a pathologist, but on all samples, 
accurately re-examined with Ziehl-Neelsen staining, no 
acid-fast bacteria were demonstrated. One month after 
discharge the patient appeared to be in good general con-
ditions, symptomless and with a progressive recovery of 
body weight. A subsequent MRI of the upper and lower 
abdomen, performed with and without contrast, did not 
show any wall thickening or any other abnormal find-
ing in any of the explored colic segments. Upon further 
clinical examination, performed three months later, the 
patient was in good health with a complete recovery of 
body weight and normal laboratory tests.
Discussion
Crohn’s disease and intestinal TBC share several clini-
cal and histological features, thus determining problems 
of differential diagnosis. The case herein represents an 
example of an insidious differential histological diagno-
sis due to the absence of complete clinical data. If a cor-
rect diagnosis can be relatively easier to suspect in areas 
of high tubercular prevalence, this is not the case in geo-
graphical areas such as Europe, especially Western Eu-
rope, where tuberculosis is rarely seen. In our case, cor-
rect diagnosis was achieved only after an unfavourable 
clinical course and an unsatisfactory therapeutic re-
sponse, which prompted consideration for treatment 
with a biological drug. Routine pre-treatment chest X-
ray was the pivotal finding that prompted us to re-evalu-
ate the patient. In fact, the absence of acid-fast bacteria 
in the revised histological samples, taken on the first co-
lonoscopy, influenced subsequent diagnostic and thera-
peutic behaviour, and it was only the chest X-ray, per-
formed when administration of a biological treatment 
was considered, that allowed for correct diagnosis. Even 
if a chest X-ray may be non diagnostic in almost half of 
cases 1 2, since less than 50% of patients affected from 
intestinal tuberculosis show clear-cut radiological marks 
of a pulmonary involvement, in our case it was the find-
ing of nodular pulmonary lesions on a chest-X ray which 
induced us to perform a CT scan, which confirmed the 
presence of nodular opacities coherent with a tubercular 
disease. Crohn’s disease and TBC seem to share a re-
duced constitutional immunity, since only 5-10% of pa-
tients infected by Mycobacterium tuberculosis develop a 
clinically active form of the disease 2. NOD2 (nucleotide 
binding oligomerization domain) and Toll-like (TLRs) 
receptors, for instance, may have a role in the early in-
ducing phase of both the diseases  2, and individual 
changes in biological interactions between the host and 
bacteria can weaken the effectiveness of the immune re-
sponse. Apart from epidemiological considerations, a 
diagnosis of Crohn’s disease relies upon anamnestic, 
clinical, endoscopic and biopsy criteria and on the exclu-
sion of a mycobacterial infection 2-4. Cigarette smoking 
is an environmental factor associated with both diseases, 
probably due to a direct action on pulmonary mac-
rophages or dendritic cells 2. The variety of extraintesti-
nal features in inflammatory bowel diseases is well 
known, but its importance is weakened by the fact that 
extrapulmonary sites may also be involved in tuberculo-
sis 2. Tuberculin reaction as a diagnostic criterion in pa-
tients with ileocolic manifestations of the disease is 
hampered by possible cross-reactions with the Calmette-
Guerain bacillus (BCG), by the local prevalence of my-
cobacterial species different from the tubercular ones 
and by diffusion of latent forms of tubercular infec-
tions 2. From a clinical point of view, both diseases may 
have an insidious onset, with chronic abdominal com-
plaints and systemic symptoms, and raise problems of 
differential diagnosis with lymphoma, adenocarcinoma 
and infectious diseases, such as for example amebiasis, 
actinomycosis or Yersinia enteritis 1. Accurate colonos-
copy, with examination of the last ileal loop and multi-
ple biopsies, is of pivotal importance in the evaluation of 
every patient with suspected Crohn’s disease or intesti-
nal tuberculosis. In the majority of cases of intestinal 
tuberculosis, the ileocaecal tract is affected. However, in 
almost 20% of patients a segmentary involvement of co-
lon is seen in the absence of any lesion in the ileocaecal 
loop 2. In 44% of cases, the so-called “skip lesions”, in-
volving two or more colonic segments alternating with 
macroscopically normal tracts, may be seen  2. Fistulae 
may be seen both in Crohn’s disease and intestinal tu-
berculosis 1. In an Indian endoscopic series including 43 
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patients  3, colonic mucosal ulcerations were present in 
70% of cases, followed by mucosal nodules (56%), ul-
cerations associated to nodularities (44%), distortion of 
caecum and ileocaecal valve (40%), luminal narrowing 
(23%), polypoid lesions (14%) and bridging fibrotic 
stripes (7%). Together with the endoscopic picture, his-
tologic examination is an important diagnostic criterion, 
particularly difficult to be correctly interpreted in areas 
of high tubercular prevalence. In intestinal tuberculosis, 
the pathognomonic marker caseous granuloma, together 
with the presence of acid-fast bacteria, can be found in 
less than 30% of cases 2 4, and a bacterial culture is une-
quivocally positive in only 20% of cases and requires a 
lengthy time for results  2 3. Lesions such as confluent, 
multiple and/or large granulomas, ulcerations surround-
ed by bands of epithelioid histiocytes, submucosal gran-
ulomas and signs of severe mucosal inflammation can 
be seen almost exclusively in intestinal TBC 2. On the 
contrary, in Crohn’s disease single granulomas and signs 
of mucosal distortion at a distance from the granulomas 
tend to prevail  2. Nonetheless, several biopsy samples 
from all colonic segments, either macroscopically in-
volved or seemingly normal, are of paramount impor-
tance. In a retrospective study from India 4, biopsy sam-
ples taken from 61 anatomic sites of 20 patients suffer-
ing from intestinal TBC were examined and compared 
to biopsy samples taken from 112 anatomic sites of 20 
patients suffering from intestinal Crohn’s disease. In pa-
tients with intestinal TBC, granulomas tended to be mul-
tiple, of greater size, confluent and often contain areas of 
caseous necrosis. Ulcerations appeared to be surrounded 
by clusters of epitheliod histiocytes and presented brisk 
submucosal inflammation. In contrast, in cases of 
Crohn’s disease granulomas appeared to be more scat-
tered, smaller and associated with foci of active colitis 
and diffuse signs of chronic inflammation, even in areas 
of normal endoscopic appearance. Among diagnostic 
imaging techniques, the role of barium X-ray examina-
tion has been declining, while contrast-enhanced CT, 
ultrasound examination and MRI are increasingly per-
formed. Using these techniques, accurate evaluation of 
intestinal parietal alterations, mesenterial lesions and lo-
cal lymph-nodes network can be made 2. A possible role 
of laparoscopy in the differential diagnostic work-up 
between intestinal tuberculosis and Crohn’s disease has 
not yet been validated by systemic studies 2. Anti- Sac-
charomyces cerevisiae antibodies (ASCA), which can 
be positive in 60-80% of patients suffering from Crohn’s 
disease, are not useful in differential diagnosis  5. In a 
recent study from the USA 6, the problem of differential 
diagnosis between Crohn’s disease and intestinal tuber-
culosis has been approached by comparing several pa-
rameters in two groups, each with 53 patients, suffering 
from one or the other disease. Together with past history 
and clinical data, histological findings were re-exam-
ined, with particular attention to ulcerations, architec-
tural changes, kind of damage to crypts and type of 
granulomas and inflammation. A multivariate analysis 
identified, as possible independent predictive factors of 
intestinal tuberculosis, compared to Crohn’s disease, 
four diagnostic criteria, namely presence of blood in fae-
ces, weight loss, involvement of the sigmoid colon and 
presence of a focally-active colitis. However, the au-
thors cautioned that these data need to be confirmed in 
further studies before being implemented in clinical 
practice. In our case, the point completely ignored in the 
initial work up of the patient was geographical origin, 
since some areas of Eastern Europe have a higher tuber-
cular prevalence compared to Western Europe. The fact 
that the histologic samples which were revised after cor-
rect diagnosis did not show acid-fast bacteria could be 
related to scanty biopsy sampling. A further cause of the 
diagnostic delay was the lack of a chest X-ray on the oc-
casion of the first hospital admission. This was per-
formed only in a later phase of the clinical course, when 
it was decided to administer a biological treatment, and 
was of crucial importance in achieving correct diagnosis 
and starting effective treatment.
On the basis of our experience,  a correct diagnosis can 
usually be made only through careful clinical history, 
accurate physical examination and complete diagnostic 
testing.
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Introduction
The round ligament of the liver is part of its means of 
fixation  1. Tumours can grow in any cells of the liver, 
for example in the parenchyma, in the epithelium of the 
biliary ducts, in the vascular structures and in any mes-
enchymatous tissue. Tumours in the round ligament are 
very rare 2-6. In the last 5 decades few cases have been 
reported worldwide. 
Case report
A 40-year-old white female patient, from a rural ar-
ea, who had been apparently healthy, presented to the 
outpatient General Surgery’s ward at “Vladimir Ilich 
Lenin” Provincial Teaching Hospital, in Holguín prov-
ince, Cuba, complaining of a recurrent mesogastric pain 
which had lasted for 3 months. The pain was of variable 
intensity and insidious, without a well defined radiation, 
and with no accompanying symptoms. She had some re-
lief with analgesics.
On examination an abdominal mass was found, palpable 
in both the mesogastrium and the right hypochondrium, 
which measured approximately 8 centimetres, rounded in 
shape with regular borders, flat surface, hard and movable. 
On palpation there was no tenderness. She was hospitalized 
with the presumptive diagnosis of an abdominal tumour. 
On investigation, laboratory studies, including liver 
function tests, were within normal limits. Chest X-ray 
showed no particular pleuropulmonary lesions. The ab-
dominal ultrasound revealed a 60 by 50 cm well defined 
rounded heterogeneous image of refringent contours, 
with multiple calcifications of small size, located in the 
mesogastric area, to the right of the middle line (Fig. 1) 
but, with no defined origin of the tumour.
Abdominal CT  showed a very dense image in the ab-
dominal cavity, 40-50 HUs, 71 by 56 mm, homoge-
neous, with inner dotted calcifications, that produced, 
after the injection of contrast medium, an intense non-
homogenous enhancement, with a pedicle that adhered 
to the abdominal wall at the level of the umbilical scar, 
displacing adjacent intestinal structures, with a well de-
fined flat contour. (Fig. 2) 
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A 40-year-old Caucasian female patient presented to the out-
patient General Surgery ward in “V. I. Lenin” Teaching Hospi-
tal complaining of a recurrent mesogastric pain that had lasted 
for 3 months. Physical examination showed a palpable mass 
confined to that area. She was then admitted with diagnosis 
of an abdominal tumour. Diagnostic work-up revealed that the 
process involved the round ligament of the liver, which is an 
exceptional localization, which motivated us to publish this 
case after surgical treatment by excision, having also taken 
into account the results of histopathology which revealed a 
PEComa, confirmed by inmunohistochemistry. After review-
ing the available literature, the low incidence of these lesions, 
as well as the unusual histological variety, makes the present 
case one of interest. 
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A laparoscopy revealed a 7 cm round formation, in the 
round ligament of the liver, with whitish areas in the 
lower part and areas of dark red colour with vascular 
appearance. These vessels were mostly dilated in the up-
per part of this structure. It was concluded that it was a 
tumour of the hepatic round ligament.
In August 2012 she was treated surgically. The tumour was 
identified and removed by laparotomy. It was a well encap-
sulated, 8 to 10 cm round, hard tumour, with flat and regu-
lar borders, and intense red colour contrasting with whitish 
areas with calcifications. It had several dilated superficial 
vessels; its pedicle extended up to the umbilical scar. 
The removal of the tumour and the round ligament were 
carried out completely, including segments of the peri-
toneum, aponeurosis and muscle, which were in direct 
relationship with the neoplasm. The entire abdominal 
cavity was examined, and no metastasis in the liver or 
any neighbouring organ were revealed, with no intra-
abdominal adenopathies. (Fig. 3).
Histopathology was consistent with a perivascular epi-
thelioid cell tumour (PEComa) of the round hepatic liga-
ment, sclerosing variant, immunohistochemically posi-
tive for caldesmon, HMB-45 and Ki67, negative for CK 
and S100, in less than 10% of the neoplastic cells. (Fig. 4). 
Discussion
Primary tumours of the round ligament of the liver are 
extremely rare 7. The main clinical features are unspeci-
fied symptoms, for instance, abdominal pain; an epigas-
tric or mesogastric palpable mass can be found. Its diag-
nosis may be reached as an incidental discovery during 
preoperative work-up or upon laparotomy.
Several histological subtypes have been described spo-
radically in the medical literature 8, benign or malignant 
in nature. In the year 2000, Folpe 9 described a new mem-
ber of the family of PEComas, the clear cell myomelano-
cytic tumour of the falciform ligament/ligamentum teres, 
which show predilection for children and young adults. 
Metastasis of gastrointestinal cancers can be found at 
this site, particularly mucinogen appendiceal neoplasm, 
peritoneal mesothelioma, and rarely breast cancer and 
hepatocarcinoma 10-12.
Fig. 1. Ultrasonographic image showing the tumour with unde-
fined origin.
Fig. 2. ct image after injection of contrast medium showing non-
homogeneous enhancement of the tumour. 
Fig. 3. Surgical specimen. the tumour and round ligament 
weighed 200 gm.
Fig. 4. immunohistochemical features. a: positivity for hMB-45 
immunostaining. B: positivity for caldesmon. S-100 and cK pro-
teins were negative.
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The PEComa in our case had a variable immunohisto-
chemical expression for smooth muscle and melanocytic 
markers. At present, their natural history is often unfore-
seeable 13; some cases have been described with just a few 
or some symptoms, while others have shown more alarm-
ing symptoms like abdominal pain with bleeding 14.
The PEComas are mesenchymal neoplasms that include 
the clear cell “sugar” tumour of the lung and extra pulmo-
nary sites, angiomyolipoma, clear cell myomelanocytic 
tumour of the falciform ligament/ligamentum teres, and 
rarely lymphangioleiomyomatosis-like tumours 15. They 
affect predominantly female patients and young adults. 
They have been identified in several anatomical loca-
tions such as the liver, uterus, vulva, rectum, heart, 
breast, urinary bladder, abdominal wall and pancreas 16.
In 1992, Bonetti proposed the concept of PEComa, and 
the term was introduced for the first time by Zamboni 
4 years later. In the year 2003, after initial scepticism, 
the WHO defined PEComas as mesenchymal tumours. 
A current hypothesis is that these neoplasms derive from 
undifferentiated cells of the neural crest with smooth 
muscle and melanocytic phenotype, a second is that they 
have a myoblastic origin from smooth muscle and a third 
involves a pericytic origin. Histology with immunostain-
ing is usually necessary to make a correct diagnosis 17 18.
These tumours express positive staining for myogenic 
and melanocytic markers such as HMB45, HMSA-1, 
MelanA/Mart1, MIB-1, CD31 and micro-ophthalmia 
transcription factor (Mitf), smooth muscle actin (SMA) 
and desmin. Immunoreactivity for vimentin is usually 
unremarkable, being negative for protein S-100, cyto-
keratin-AE1/AE3, cytokeratin-5 and CD30. 
About 100 PEComas have been reported, 38 from the 
uterus. Those of the liver are extremely rare and only a 
small number of cases have been reported so far. 
Surgical resection represents the only healing procedure 
for a primary PEComa, because chemotherapy and ra-
diotherapy have not demonstrated significant benefits 19. 
Only a few recent clinical studies have reported encour-
aging results related to therapy, after the oral administra-
tion of the inhibitor mTOR in patient with metastasis 20. 
Recently, Folpe and colleagues have suggested malig-
nancy criteria including a size bigger than 5  cm, high 
mitotic count of more than 1 per 50 high-power fields 
and necrosis.
The patient was discharged 48 hours after surgery, and 
has had an uneventful follow-up up to date. 
Conclusions
Primary PEComas of the round ligament of the liver are 
rare, difficult to diagnose, and are usually found during 
laparotomy or for a medical check-up for other condi-
tions; diagnostic laparoscopy can be of enormous help for 
making a correct diagnosis and to choose appropriate sur-
gery. As far as we know, this is the first case of a PEComa 
of the round ligament of the liver reported from Cuba.
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Introduction
Pleomorphic adenoma is the most common neoplasm of 
the salivary glands. It is usually a benign, slow-growing 
and well-circumscribed tumour. However, a few of these 
tumours metastasize to distant sites without undergoing 
malignant transformation 1. In the 2004 WHO classifi-
cation of salivary glands tumours, the term “Malignant 
Mixed Tumours” includes three subtypes: carcinoma ex 
pleomorphic adenoma (CEPA), carcinosarcoma (or true 
malignant mixed tumour) and the metastatic mixed tu-
mours  2. We report a case of multiple cervical lymph 
node metastasis originating from a histologically benign 
pleomorphic adenoma of the submandibular gland.
Case report
A 38-year-old woman, native of Sudan, with a history 
of recurrent pleomorphic adenoma of the submandibu-
lar gland, resected the first time 20 years ago, presented 
with a slowly growing and painless swelling of the left 
submandibular gland.
Both physical examination and cervical ultrasound 
(Fig. 1) revealed the presence of multiple asymptomatic 
lymph nodes on both sides of the neck (submandibu-
lar, upper and midjugular chains) that were not fixed to 
underlying tissues or the overlying skin. Parotid glands 
were normal. 
Under general anaesthesia, biopsies followed by frozen 
sections of the submandibular lump and cervical lymph 
nodes were obtained, showing in both locations a typical 
pleomorphic adenoma with no evidence of extracapsu-
lar growth, atypia, vascular or perineural involvement at 
histological examination. 
Total resection of the submandibular gland with bilateral 
neck dissection at level II was performed. 
On gross examination, the submandibular gland mea-
sured 4 cm in diameter, showed a nodular white lesion 
that measured 1.3  cm. We received 13 jugular lymph 
nodes and 6 submandibular lymph nodes.
Microscopically, the submandibular gland tumour dis-
played histopathological features consistent with a MPA 
(Figs. 2 and 3). It was composed of tubules, ductal struc-
tures, trabeculae and small aggregates. The ducts were 
lined with an inner layer of cuboidal cells and an outer 
layer of flat myoepithelial cells. A distinctive hyaline 
and fibromyxoid stroma was present. Margins of the 
surgical specimen were free of tumour. Immunostain-
ing for oestrogen receptors (6F11, Novocastra, 1/40) 
and progesterone receptors (PgR 636, DAKO, 1/40) was 
negative. 
On the 19 lymph nodes received, 10 were metastatic and 
showed the same biphasic proliferation described previ-
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Pleomorphic adenoma (PA), originally called mixed tumour, 
is the most common neoplasm of the salivary glands. It is usu-
ally a benign, slow-growing and well-circumscribed tumour. 
However, PA may occasionally give rise to metastases that 
usually occur after a previous recurrence. These tumours dis-
play benign histological features in both primary tumours and 
metastases. Such tumours have been termed metastatic PA or 
metastatic mixed tumours. We report a case of metastatic PA 
of the submandibular gland with metastasis to the cervical 
lymph nodes.
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ously (Fig. 4). The histological features were consistent 
with a diagnosis of metastasizing pleomorphic adenoma. 
Chest radiography was within normal limits. The post-
operative course was uneventful. The patient remains 
asymptomatic on follow-up at 8 months. 
Discussion
Metastasizing pleomorphic adenoma (MPA) was first 
described in 1942, and up to 80 cases have since been re-
ported 3. Benign MPA is distinguished from truly malig-
nant pleomorphic tumours (such as carcinomas arising 
from pleomorphic adenomas) by its benign histological 
features. MPA of the salivary glands is a rare neoplasm 
that raises controversy over its nomenclature and its true 
biological nature. These neoplasms were termed in early 
reports as metastatic benign mixed tumours, a term that 
is confusing, since the terms benign and metastatic are 
paradoxical 2. They have also been termed metastasizing 
mixed tumours (MZMTs). In the last WHO classifica-
tion of salivary gland tumoyrs 2, they have been included 
in the category of malignant epithelial tumours and clas-
sified as metastasizing pleomorphic adenoma.
There is no age or sex predilection. The average age is 
of presentation is 41 years  4 5. A literature search using 
PubMed retreived 50 cases of MPA reported during the 
last three decades. Primary tumour sites were the parotid 
gland (33 cases), submandibular gland (11 cases) and 
minor salivary glands (6 cases all located in the soft pal-
ate). There was no case of MPA reported in the sublin-
gual gland. These tumours usually present with multiple 
local recurrences  6. The interval between diagnosis of 
primary pleomorphic adenoma and metastases varies be-
tween 3 and 52 years after the occurrence of the primary 
tumour 6  7. Bone is the most common site for metastases, 
followed by regional lymph nodes and lung. Metastatic 
deposits have also been discovered in the oral cavity, 
skin, liver, retroperitoneum, kidney and central nervous 
system. The metastases occur either simultaneously with 
Fig. 1. cervical ultrasound shows an enlarged lymph node.
Fig. 2. h.E x 40: a submandibular gland partially replaced by a well 
circumscribed tumor showing both epithelial and mesenchymal 
differentiation.
Fig. 3. h.E. x 100: the epithelial component consists of well 
formed ducyal structures, lined by regular cells. the mesenchy-
mal component is fibrous, with regular fibroblasts.
Fig. 4. h.E. x 200: lymph node parenchyma replaced by a bipha-
sic cellular proliferation, without cytonuclear atypia, leaving a pe-
ripheral rim of residual lymphoid tissue. 
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an episode of recurrent pleomorphic adenoma or many 
years after a recurrence 6 8. In our case, both the primary 
lesion and the cervical nodal metastasis presented simul-
taneously, almost 20 years after the occurrence of the ini-
tial tumour.
The mechanism underlying the metastatic behaviour 
of MPA is still uncertain. As most MPA occurred after 
surgical treatment of primary or recurrent lesions of the 
salivary gland, one hypothesis suggests that surgical ma-
nipulation may cause tumour cell dislodgement, hema-
togenous spread and subsequent implantation at distant 
sites. More probably, the metastatic potential of PA is 
the result of key genetic alterations that cause histologi-
cal and biological progression. Nevertheless, no recur-
rent cytogenetic abnormalities have been reported 3 9.
Histopathological examination of pleomorphic adenoma 
from the primary site and from the metastasis usually 
shows a typical biphasic pattern with a chondromyxoid 
stroma without any sign of malignancy. These tumours 
present more frequently with focal absence of the cap-
sule, and with satellite nodules. Some authors suggest 
that the presence of both mitotic activity and an infil-
trative growth pattern in the primary tumour could be 
predictive of the metastatic potential of PA 10 11. 
There are a few cases in the literature documenting the 
expression of oestrogen and progesterone receptors in 
MPA. Larbcharoensub et al. 12 found expression of pro-
gesterone receptors in the mesenchymal component of 
MPA. The present findings suggest that expression of 
hormonal receptors may play a role in the development 
of MPA, and also raise the possibility that these tumours 
could respond to hormone therapy. In our case, oestro-
gen receptors and progesterone receptors were negative.
MPA remains an aggressive disease. The percentage of 
patients dying of metastatic disease is quite high (22%), 
and therefore these neoplasms should not be considered as 
benign in spite of their benign histological features. Some 
authors prefer to classify metastatic PA as low-grade ma-
lignant salivary gland neoplasms. Unfortunately, there is 
no clinical, histopathological or molecular findings that 
can predict an eventual metastatic course of PA 2 11.
According to Nouarej et al.  13, in a virtual series of all 
identified cases of MPA reported in the literature over 
almost 50 years, found that independent prognostic fac-
tors were the occurrence of metastasis in a single or mul-
tiple site, and the interval between the initial tumour and 
the occurrence of metastasis. 
Patients presenting with metastatic lesions in multiple 
sites had significantly worse prognosis compared with 
patients whose metastases were in multiple sites. Pa-
tients presenting with MPA within 10 years of their ini-
tial primary tumour had a significantly worse prognosis 
compared with those whose metastases were detected 
more than 10 years after the initial PA 14.
Treatment of MPA is mainly surgical. It usually consists of 
local tumour resection, and metastasectomy, irrespective 
of the distant site. Metastasectomy confers a significant 
survival advantage over non-operative treatment 2  6  14. Ad-
juvant radiotherapy is sometimes indicated. 
Conclusion
Metastasizing pleomorphic adenoma is a very rare neo-
plasm that is actually considered as a malignant tumour. 
It probably complicates the course of an incompletely 
resected pleomorphic adenoma. Therefore, the quality 
of the primitive tumour resection is crucial. 
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Introduction
Supernumerary breasts are a known entity with report-
ed incidence of 1-6 % 1. This is attributed to the failure 
of regression of milk line remnants during embryogen-
esis. Although rare, an increasing number of cases of 
ectopic breast tissue in the vulva have been described 
since Hartung first reported a fully formed mammary 
gland in the vulva in 1872, which is known to develop 
a variety of pathologic changes  2  3. Ectopic breast fi-
broadenoma of the vulva is extremely rare, although 
this entity should not be overlooked since some may 
become neoplastic.
Case report
A 37-year-old woman was referred to our institution 
complaining of a 6-month history of vulvar mass with 
progressive growth. Previous medical and familial his-
tory was not contributory to the present illness. Upon 
physical examination, a solitary pedunculated softy 
mass located on the right labium majus was observed. 
The patient was admitted and underwent surgical in-
tervention. The entire mass was completely removed. 
Grossly, a smooth mass measuring 7  x  3.5  x  2.5  cm, 
covered by skin, was obtained. Cut surface showed a 
yellowish-white nodule, well delimited, measuring 4 
cm (Fig. 1). Microscopic examination revealed a benign 
fibroepithelial lesion showing proliferation of both the 
stromal and the glandular component with a few ducts 
being dilated. The epithelium was double layered with a 
cuboidal luminal layer and a basal myoepithelial layer. 
The fibrosis area was abundant. The tumour was circum-
scribed and separated from the coat by connective tissue. 
Morphologically, the appearance was consistent with a 
fibroadenoma of the mammary gland (Figs. 2, 3). Im-
munohistochemical staining was performed. Immuno-
reactivity of oestrogen and progesterone receptors was 
detected in tumour tissue.
Discussion
Vulvar fibroadenoma is one of the mammary-like fi-
bro epithelial lesions with controversial histogenesis. 
The traditional theory regarding the occurrence of su-
pernumerary breast tissue is that it is an embryologi-
cal mammary remnant. Foushee and Pruitt suggest that 
fibroadenoma arise in ectopic breast tissue  4. How-
ever, Vander Putt states that many lesions previously 
reported as associated with the supernumerary mam-
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Ectopic breast tissue is defined as glands located outside of the 
breast. It can be found anywhere along the milk line extending 
from the axilla to the groin, and can occur in the vulva. Ectopic 
breast tissue should be excised because it may develop benign or 
malignant pathologic processes. Less than 40 cases of fibroad-
enoma in the vulva have been reported in the literature. We report 
a case of a 37-year-old woman presenting a solitary vulvar mass. 
The mass was excised completely, and histology demonstrated an 
ectopic breast fibroadenoma. This is one of the few reports on the 
benign pathologies of vulvar mammary glands.
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mary glands are in fact derived from the mammary–
like anogenital glands  5. As a rule, vulvar breasts do 
not attract attention until they become enlarged or ac-
tive (pregnancy, puberty, lactation). Ectopic tissue may 
be associated with malignancies and other congenital 
abnormalities such as pyloric stenosis, epilepsy and 
especially urinary tract abnormalities 6. Renal malfor-
mations and renal adenocarcinoma are the most com-
mon abnormalities seen in patients with polymastia 6. 
Aberrant tissue is capable of behaving in the same way 
as normally situated breasts, and responds to hormonal 
influences at puberty, during the menstrual cycle and 
during pregnancy and lactation. Both benign and ma-
lignant pathologic processes may occur. Average pa-
tient age at moment of diagnosis is 38.7 years (range, 
20-60 years)  7 8, and the average tumour size is 3 cm 
(range, 0.8-6 cm) 3. Biopsy of the vulvar mass is impor-
tant for differential diagnosis, and to make an appropri-
ate surgical decision in case of ectopic breast tissue. If 
it is malignant, a wider excision with lymph node dis-
section must be considered. If it is benign, then simple 
excision is sufficient. Diagnosis is based on histologi-
cal findings in association with immunohistochemical 
features. Fibroadenoma originating from an ectopic 
breast should be taken into consideration in differential 
diagnosis of vulvar mass.
Conclusion
Vulvar heterotopic breast is rare and can present a chal-
lenge for both the clinician and the surgical pathologist 
in making a correct diagnosis. Histopathological con-
firmation is mandatory to exclude the possibility of an-
other tumour, including malignancy, and to eliminate a 
neoplastic process in the ectopic breast tissue. 
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